ASLAN PHARMACEUTICALS : INITIATES PHASE 2B STUDY OF ASLAN004 (EBLASAKIMAB) IN MODERATE-TO-SEVERE ATOPIC DERMATITIS - Form 6-K

ASLANPHARMACEUTICALSINITIATESPHASE2BSTUDYOFASLAN004(EBLASAKIMAB)INMODERATE-TO-SEVEREATOPICDERMATITIS

-

TheTRialswithEblasaKimabinAtopicDermatitis(TREK-AD)studywillevaluatetheefficacyandsafetyofASLAN004,nowknownaseblasakimab,apotentialfirst-in-classantibodytargetingtheIL-13receptor

-

Thisdose-rangingstudyisexpectedtoenrollapproximately300patients andwillevaluate4doseregimens

-

Toplineresultsareexpected in1H2023

Menlo Park,California,and Singapore,January 20, 2022-ASLAN Pharmaceuticals(Nasdaq: ASLN), aclinical-stage,immunology-focusedbiopharmaceutical companydeveloping innovativetreatmentstotransformthelivesofpatients,today announcedthat ithasscreenedthefirstpatientinits Phase2bdose-rangingclinicalstudy ofeblasakimabinadults withmoderate-to-severeatopicdermatitis(AD).Eblasakimabisapotential first-in-classmonoclonal antibodytargetingtheIL-13receptorthat hasthepotentialtoprovidea differentiatedtreatmentoptionforpatients.ASLAN expectstoreporttoplinefindingsfrom the16-weektreatmentperiodinthefirsthalfof2023.

The randomized,double-blind,placebo-controlled,dose-ranging clinical studywillevaluatetheefficacyandsafety ofeblasakimabinadultpatients withmoderate-to-severe ADwhoare candidatesforsystemictherapy. The TREK-ADstudy will randomize patients equally tofouractivetreatmentarms and oneplaceboarm, evaluatingeblasakimab300mg dosed every twoweeks, 400mgdosed every twoweeks, 400mg dosed every four weeksand600mg dosedevery four weeks.

The study is expectedtoenrollapproximately 300 adultpatientsacross 100sites in NorthAmerica, EuropeandAsiaPacificandwillconsistof a 16-weektreatmentperiodanda 12-weeksafetyfollow-upperiod. The primary efficacyendpointis percentagechange inEczema Area SeverityIndex(EASI)score from baseline to week 16. Key secondaryefficacyendpointsincludetheproportionofpatients achievingInvestigator Global Assessment(IGA) score of 0(clear)or 1(almostclear),proportionofpatients witha 75%orgreater reductioninEASI (EASI-75),proportionofpatientsachieving EASI-50andEASI-90,andchanges inpeak pruritus.Furtherdetails are available viaClinicalTrials.gov(study IDNCT05158023).

DrCarlFirth, CEO, ASLANPharmaceuticals,commented,"Weare pleased to haveinitiatedthis importantnew studyevaluatingeblasakimabin moderate-to-severeADpatients. Building uponthepositive datawe recentlyannouncedfromthe Proof-of-Conceptstudy,thePhase2b programwill enableusto evaluateitspotentialasanovel treatmentoption thatcouldprovidemeaningfulimprovements over existing therapies. This isakey milestonefor ASLANandmovesuscloser towardsdemonstrating thepositive impactthateblasakimabcould haveon theburden of diseaseforatopicdermatitisandfor other Type2drivenallergicdiseases."

Ends

Media and IRcontacts

Emma ThompsonSpurwing CommunicationsTel:[phone]

Email:[e-mail]

AshleyR.RobinsonLifeSciAdvisors,LLCTel:[phone]

Email:[e-mail]

AboutASLANPharmaceuticals

ASLAN Pharmaceuticals(Nasdaq:ASLN)isaclinical-stage, immunology-focused biopharmaceutical companydeveloping innovativetreatmentstotransformthelivesofpatients. ASLANiscurrentlyevaluatingeblasakimab,apotential first-in-classantibody targeting theIL-13receptor,inatopicdermatitis, andASLAN003,apotent oral inhibitor ofDHODH, whichisbeing developedforautoimmunedisease.ASLAN hasateam inMenloPark,California, andin Singapore. Foradditional informationpleasevisit www.aslanpharma.comorfollow ASLANon LinkedIn.

About eblasakimab(ASLAN004)

Eblasakimab, alsoknownasASLAN004,isanovel,first-in-classmonoclonal antibodythattargetstheIL-13receptorα1subunit(IL-13Rα1),oneofthecomponentsoftheType2receptor. Byblocking theType2receptor,eblasakimabpreventssignaling throughbothinterleukin4(IL-4)andinterleukin13(IL-13)-thekeydriversofinflammationinatopicdermatitis. The uniquemechanism ofactionhasthepotential todeliveradifferentiatedsafetyandefficacyprofileaswell asanimproveddosing regimen.

About theeblasakimab(ASLAN004)Proof-of-Conceptstudy

A double-blind,randomized,placebo-controlled,Phase 1bmultipleascending dosetrial was conductedtoassess thesafetyandefficacyof eblasakimabinmoderate-to-severeAD. Toplineresultsdemonstratedthatthekeyprimaryandsecondaryendpointsweremet, andsupportedthepotential of eblasakimabasa differentiated,noveltreatmentforAD. IntheITTpopulation,eblasakimabachievedastatisticallysignificantimprovementof 61% versus32% intheplacebogroupintheprimaryefficacyendpointof percentchangefrom baselineinEczemaAreaSeverity Index (EASI)at8weeks andstatisticallysignificantimprovements inotherkeyefficacyendpoints:EASI-50, EASI-75,peakpruritus,andthePatient-OrientedEczemaMeasure(POEM).50% ofpatientswhoreceivedeblasakimab600mg weeklyachievedEASI-75,comparedto 13% ofpatientsreceivingplacebo.Eblasakimabwaswell-toleratedacrossalldoseswithnoemerging safetyconcerns.

Forward-Looking Statements

Thisreleasecontainsforward-looking statements.ThesestatementsarebasedonthecurrentbeliefsandexpectationsofthemanagementofASLAN PharmaceuticalsLimitedand/oritsaffiliates(the"Company"). Theseforward-looking statementsmay include, butarenotlimitedto, statementsregarding theCompany'sbusinessstrategyandclinical developmentplans;theCompany'splanstodevelopandcommercialize eblasakimab;thesafetyandefficacyof eblasakimab;theCompany'splansandexpectedtiming withrespecttoclinical trials, clinical trialenrolmentandclinical trial resultsforeblasakimab;andthepotential for eblasakimabasafirst-in-classtreatment foratopicdermatitis. TheCompany'sestimates,projectionsandotherforward-looking statementsarebasedonmanagement'scurrentassumptionsandexpectationsoffutureeventsandtrends, whichaffect ormayaffect theCompany'sbusiness, strategy,operations,orfinancialperformance, andinherentlyinvolvesignificantknownandunknownrisks anduncertainties. Actual resultsandthetiming ofeventscoulddiffermateriallyfrom thoseanticipatedinsuchforward-looking statementsasaresultofmanyrisks anduncertainties, whichinclude,unexpectedsafetyorefficacydataobservedduring preclinical or clinical studies;clinical siteactivationratesorclinical trial enrolmentratesthatarelowerthanexpected;theimpact oftheCOVID-19pandemicontheCompany'sbusinessandtheglobal economy;general marketconditions;changesinthecompetitivelandscape;andtheCompany'sabilitytoobtainsufficientfinancing tofunditsstrategicandclinical developmentplans. Other factors

thatmaycauseactual resultstodifferfrom those expressedorimpliedinsuchforward-looking statementsaredescribedintheCompany'sUSSecuritiesandExchangeCommissionfilingsandreports(CommissionFileNo.001-38475), including theCompany'sAnnual ReportonForm20-FfiledwiththeUSSecuritiesandExchangeCommissiononApril 23,2021. All statementsotherthanstatementsofhistorical fact areforward-looking statements. The words"believe,""may,""might,""could,""will,""aim,""estimate,""continue,""anticipate,""intend,""expect,""plan,"orthenegativeof those terms, andsimilarexpressionsthatconvey uncertaintyoffutureeventsoroutcomesareintendedtoidentifyestimates, projections, andotherforward-looking statements. Estimates, projections, andotherforward-looking statementsspeakonlyasofthedatethey weremade, and, excepttotheextentrequiredbylaw,theCompanyundertakesnoobligationtoupdateorreviewanyestimate, projection, orforward-looking statement.